WO2003076561A2 - Proteine de fusion a recombinase presentant un apport cellulaire ameliore - Google Patents

Proteine de fusion a recombinase presentant un apport cellulaire ameliore Download PDF

Info

Publication number
WO2003076561A2
WO2003076561A2 PCT/EP2003/002280 EP0302280W WO03076561A2 WO 2003076561 A2 WO2003076561 A2 WO 2003076561A2 EP 0302280 W EP0302280 W EP 0302280W WO 03076561 A2 WO03076561 A2 WO 03076561A2
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
seq
domain
cre
cells
Prior art date
Application number
PCT/EP2003/002280
Other languages
English (en)
Other versions
WO2003076561A3 (fr
Inventor
Frank Oliver Stefan Edenhofer
Michael Peitz
Kurt Pfannkuche
Klaus Rajewski
Original Assignee
Artemis Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02005468A external-priority patent/EP1342781A1/fr
Application filed by Artemis Pharmaceuticals Gmbh filed Critical Artemis Pharmaceuticals Gmbh
Priority to AU2003210422A priority Critical patent/AU2003210422A1/en
Publication of WO2003076561A2 publication Critical patent/WO2003076561A2/fr
Publication of WO2003076561A3 publication Critical patent/WO2003076561A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne une protéine de fusion comprenant un domaine de recombinaison d'ADN spécifique à un site, tel que la Cre recombinase, et un domaine contenant un signal de localisation nucléaire modifié spécifique. La protéine de fusion peut également comprendre un domaine de transduction de protéine tel que le FGF hydrophobe et le peptide TAT basique. Le signal de localisation nucléaire spécifique seul ou avec le domaine de transduction de protéine favorise l'apport cellulaire de la recombinase. La protéine de fusion est un outil essentiel dans le génie génétique des génomes mammifères. L'invention concerne également des séquences d'ADN codant pour ladite protéine de fusion, des méthodes de production de ladite protéine de fusion, et son utilisation en tant qu'agent d'induction du ciblage d'un gène chez un organisme vivant ou dans des cellules en culture.
PCT/EP2003/002280 2002-03-09 2003-03-06 Proteine de fusion a recombinase presentant un apport cellulaire ameliore WO2003076561A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003210422A AU2003210422A1 (en) 2002-03-09 2003-03-06 Recombinase fusion protein with enhanced cellular uptake

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP02005468A EP1342781A1 (fr) 2002-03-09 2002-03-09 Protéine de fusion de recombinase avec une assimilation cellulaire accrue
EP02005468.0 2002-03-09
US36379702P 2002-03-13 2002-03-13
US60/363,797 2002-03-13

Publications (2)

Publication Number Publication Date
WO2003076561A2 true WO2003076561A2 (fr) 2003-09-18
WO2003076561A3 WO2003076561A3 (fr) 2004-01-22

Family

ID=27806514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/002280 WO2003076561A2 (fr) 2002-03-09 2003-03-06 Proteine de fusion a recombinase presentant un apport cellulaire ameliore

Country Status (2)

Country Link
AU (1) AU2003210422A1 (fr)
WO (1) WO2003076561A2 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005001062A3 (fr) * 2003-06-25 2005-04-28 Gencia Corp Vecteurs modifies pour la transfection d'organite
WO2007132555A1 (fr) * 2006-05-11 2007-11-22 The University Of Tokyo Peptide traversant les membranes cellulaires et utilisation dans une cellule
EP2120987A1 (fr) * 2007-03-02 2009-11-25 Arbor Vita Corporation Traitement des incidents cérébrovasculaires et d'autres maladies sans inhibition des canaux calcium de type n
US8039587B2 (en) 2003-10-24 2011-10-18 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8603967B2 (en) 2009-07-29 2013-12-10 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
US8673845B2 (en) 2009-07-29 2014-03-18 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
US8673846B2 (en) 2009-11-02 2014-03-18 Toagosei Co. Ltd. Cell proliferation-promoting peptide and use thereof
US8710005B2 (en) 2009-04-10 2014-04-29 Toagosei Co., Ltd. Neuronal differentiation-inducing peptide and use thereof
US20140127162A1 (en) * 2012-11-01 2014-05-08 California Institute Of Technology Reversible gene expression
US8822408B2 (en) 2010-06-04 2014-09-02 Toagosei Co., Ltd. Cell growth-promoting peptide and use thereof
JP2015208308A (ja) * 2014-04-30 2015-11-24 国立大学法人名古屋大学 投射経路選択的な遺伝子発現制御
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
WO2017026779A1 (fr) * 2015-08-10 2017-02-16 Cellivery Therapeutics, Inc. Protéine recombinée cre à perméabilité cellulaire améliorée (icp-cre) et son utilisation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001086989A (ja) * 1999-09-17 2001-04-03 Univ Osaka 哺乳類型Ｃｒｅリコンビナーゼ遺伝子
WO2001049832A2 (fr) * 2000-01-07 2001-07-12 Artemis Pharmaceuticals Gmbh Transduction de recombinases pour ciblage genetique inductible

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001086989A (ja) * 1999-09-17 2001-04-03 Univ Osaka 哺乳類型Ｃｒｅリコンビナーゼ遺伝子
WO2001049832A2 (fr) * 2000-01-07 2001-07-12 Artemis Pharmaceuticals Gmbh Transduction de recombinases pour ciblage genetique inductible

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [Online] 23 August 2001 (2001-08-23) UNIV OSAKA: "Mammalian Cre recombinase" Database accession no. AAB98695 XP002200325 *
HODEL ET AL.: "Dissection of a Nuclear Localization Signal" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 2, 12 January 2001 (2001-01-12), pages 1317-1325, XP002200324 *
JO ET AL.: "Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase" NATURE BIOTECHNOLOGY, vol. 19, October 2001 (2001-10), pages 929-933, XP002200323 cited in the application *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005001062A3 (fr) * 2003-06-25 2005-04-28 Gencia Corp Vecteurs modifies pour la transfection d'organite
US8039587B2 (en) 2003-10-24 2011-10-18 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
WO2007132555A1 (fr) * 2006-05-11 2007-11-22 The University Of Tokyo Peptide traversant les membranes cellulaires et utilisation dans une cellule
CN101678068A (zh) * 2007-03-02 2010-03-24 阿尔伯维塔公司 不抑制n型钙通道而治疗中风和其他疾病
EP2120987A4 (fr) * 2007-03-02 2010-08-18 Arbor Vita Corp Traitement des incidents cérébrovasculaires et d'autres maladies sans inhibition des canaux calcium de type n
JP2010520209A (ja) * 2007-03-02 2010-06-10 アルボー ビータ コーポレーション Ｎ型カルシウムチャネルを阻害せずに卒中および他の疾患を治療する方法
US8288345B2 (en) 2007-03-02 2012-10-16 Nono, Inc. Treating stroke and other diseases without inhibiting N-type calcium channels
AU2008223469B2 (en) * 2007-03-02 2013-09-05 Nono Inc. Treating stroke and other diseases without inhibiting N-type calcium channels
US9061070B2 (en) 2007-03-02 2015-06-23 Nono, Inc. Treating stroke and other diseases without inhibiting N-type calcium channels
EP2120987A1 (fr) * 2007-03-02 2009-11-25 Arbor Vita Corporation Traitement des incidents cérébrovasculaires et d'autres maladies sans inhibition des canaux calcium de type n
US8710005B2 (en) 2009-04-10 2014-04-29 Toagosei Co., Ltd. Neuronal differentiation-inducing peptide and use thereof
US8673845B2 (en) 2009-07-29 2014-03-18 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
US8603967B2 (en) 2009-07-29 2013-12-10 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
US8673846B2 (en) 2009-11-02 2014-03-18 Toagosei Co. Ltd. Cell proliferation-promoting peptide and use thereof
US9133437B2 (en) 2009-11-02 2015-09-15 Toagosei Co. Ltd. Cell proliferation-promoting peptide and use thereof
US8822408B2 (en) 2010-06-04 2014-09-02 Toagosei Co., Ltd. Cell growth-promoting peptide and use thereof
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
US20140127162A1 (en) * 2012-11-01 2014-05-08 California Institute Of Technology Reversible gene expression
US9943611B2 (en) * 2012-11-01 2018-04-17 California Institute Of Technology Reversible gene expression
JP2015208308A (ja) * 2014-04-30 2015-11-24 国立大学法人名古屋大学 投射経路選択的な遺伝子発現制御
WO2017026779A1 (fr) * 2015-08-10 2017-02-16 Cellivery Therapeutics, Inc. Protéine recombinée cre à perméabilité cellulaire améliorée (icp-cre) et son utilisation
US10669531B2 (en) 2015-08-10 2020-06-02 Cellivery Therapeutics, Inc. Cell-permeable Cre (iCP-Cre) recombinant protein and use thereof

Also Published As

Publication number Publication date
AU2003210422A8 (en) 2003-09-22
WO2003076561A3 (fr) 2004-01-22
AU2003210422A1 (en) 2003-09-22

Similar Documents

Publication Publication Date Title
WO2003076561A2 (fr) Proteine de fusion a recombinase presentant un apport cellulaire ameliore
AU2022200330B2 (en) Crispr-based genome modification and regulation
US9200045B2 (en) Small molecule-dependent inteins and uses thereof
JP2986915B2 (ja) 部位特異的リコンビナーゼ／核レセプタ融合タンパク質による部位特異的組換えの調節
EP3334756B1 (fr) Protéine recombinée cre à perméabilité cellulaire améliorée (icp-cre) et son utilisation
US20160145645A1 (en) Targeted integration
JP2004254697A (ja) 殺菌／浸透性が向上した安定なタンパク質生成物およびそれを含む薬剤組成物
US8993742B2 (en) Tubulo-vesicular structure localization signals
Annilo et al. Nuclear import and nucleolar accumulation of the human ribosomal protein S7 depends on both a minimal nuclear localization sequence and an adjacent basic region
WO2022109058A1 (fr) Nucléases comprenant des séquences peptidiques pénétrant les cellules
EP3372687B1 (fr) Vecteur de chromosome artificiel
EP1342781A1 (fr) Protéine de fusion de recombinase avec une assimilation cellulaire accrue
EP1395612B1 (fr) Recombinase modifiee
JP2003518947A (ja) 誘導可能遺伝子標的化のためのレコンビナーゼのトランスダクション
He et al. Nonclassical secretion of human catalase on the surface of CHO cells is more efficient than classical secretion
KR102638505B1 (ko) 개선된 단백질 발현 스트레인
EP1205490A1 (fr) Proteine de fusion comportant de integrase (phiC31) et une peptide signal (NLS)
EP1118668A1 (fr) Transduction d'une recombinase pour le ciblage inductible de gènes
WO2007012334A1 (fr) Expression de proteine amelioree
Hidema et al. Highly induced DNA recombination mediated by membrane permeabilized recombinant cre protein in mouse primary cells
CN114867854A (zh) 肽
KR100512018B1 (ko) 상동 재조합에 의해 인간 세포에서 인간 변이 단백질을 생성시키는 방법
KR20230172542A (ko) 개선된 특성들을 가진 신규한 루시페라제들
KR20230136479A (ko) 동물세포의 유전자 교정을 위한 CRISPR-Cas9 벡터 개발
CN112391366A (zh) 光诱导激活的Dre重组系统

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP